Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)
Key facts
- Who runs it
- University of Louisville
- Where
- Louisville, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 4
- Started
- 1 Mar 2024
- Ended
- 1 Jan 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Statin
- Aspirin tablet
- Nexlizet
- LEQVIO
- Vascepa
- Jardiance
- Colchicine
- Record updated
- 17 March 2025
- Why it stopped
- study withdrawn, no participants enrolled, changes in the study design planned
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Non-obstructive atherosclerotic coronary artery plaque (stenosis of 0-39% or stenosis of 40-69% with FFR-CT >0.8) in a major epicardial vessel > 2 mm in diameter
Who cannot take part
- coronary/PAD/carotid revascularization or ischemic stroke or TIA within 6 months prior to enrollment
- An organ-transplant recipient or if felt to require listing for solid organ transplantation during study status
- Known intolerance or perceived contraindication to any of the study drugs during the study period including statins or aspirin if indicated
- Chronic immunosuppression therapy
- Valvular heart disease of moderate or worse severity or requiring interventional procedures or surgery
- Pulmonary hypertension with PASP>50 mm Hg in the past 12 months
- Heart failure NYHA class 3 or 4
- Hospitalization for heart failure in the preceding 6 months
- Active malignancy (except basal cell skin cancer)
- Uncontrolled psychiatric illness
- LVEF <35% in the past 12 months
- eGFR<30 ml/min/m2
- Myocarditis or pericarditis in the past 12 months
- Known Cardiomyopathy (hypertrophic, infiltrative, restrictive, dilated, etc.)
- Life expectancy of <1 year
- Inability to give informed consent
- Cirrhosis
- ESRD
- Pregnancy or planning to conceive during the study period
- Inability to receive iodinated contrast for CCTA
Where in United States
- University of Louisville School of Medicine, Division of Cardiovascular DiseasesLouisville, United States
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the role of coronary CT angiogram (CCTA) as a superior guide for the assessment of coronary artery plaque and guiding treatment decisions. The investigators also assess the impact of preventive cardiovascular drugs on the plaque to improve patient outcomes. Participants aged 18-80 years, at intermediate or high-risk for coronary artery disease, with non-obstructive plaque on initial CCTA, will be enrolled in this study. They will be randomized into Standard of Care (SOC) vs. Aggressive Therapy (AT) groups. Both groups will undergo dietary and lifestyle interventions. Follow-up will consist of blood tests and clinic visits at baseline, 9 months, and 18 months. The second CCTA will be performed at 18 months to assess the change in plaque burden, characteristics, ischemia and pericoronary/epicardial fat.
The 2 groups in the trial
- SOC: Statin ± Aspirin (per ACC guidelines)Existing treatment, for comparison
The SOC group: participant receive routine care as per cardiologist. Study doctor will prescribe medications that they choose themselves.
Treatment: Statin and Aspirin tablet
- AT: Statin, Aspirin, Nexlizet, Leqvio, Vascepa, Jardiance, ColchicineTreatment being tested
An AT group: FDA-approved drugs will be used to reduce cholesterol and cardiovascular risk.
Treatment: Statin, Aspirin tablet, Nexlizet, LEQVIO, Vascepa, Jardiance, and Colchicine
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 17 March 2025